[go: up one dir, main page]

MX2020006754A - Moduladores de molécula pequeña de pantotenato-cinasas. - Google Patents

Moduladores de molécula pequeña de pantotenato-cinasas.

Info

Publication number
MX2020006754A
MX2020006754A MX2020006754A MX2020006754A MX2020006754A MX 2020006754 A MX2020006754 A MX 2020006754A MX 2020006754 A MX2020006754 A MX 2020006754A MX 2020006754 A MX2020006754 A MX 2020006754A MX 2020006754 A MX2020006754 A MX 2020006754A
Authority
MX
Mexico
Prior art keywords
small molecule
molecule modulators
treatment
intended
pantothenate kinases
Prior art date
Application number
MX2020006754A
Other languages
English (en)
Inventor
Robert Zamboni
Richard E Lee
Rajendra P Tangallapally
Charles O Rock
Suzanne Jackowski
Anne V Edwards
Mi Kyung Yun
Chitra Subramanian
T Jagadeeswar Reddy
Original Assignee
St Jude Childrens Res Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Jude Childrens Res Hospital Inc filed Critical St Jude Childrens Res Hospital Inc
Publication of MX2020006754A publication Critical patent/MX2020006754A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción se refiere a compuestos químicos que modulan la actividad de pantotenato-cinasa (PanK) para el tratamiento de trastornos metabólicos (tal como diabetes mellitus tipo II), trastornos neurológicos (tal como neurodegeneración asociada con pantotenato-cinasa), composiciones farmacéuticas que contienen estos compuestos y su uso en el tratamiento. Este resumen se propone como una herramienta de escaneo para propósitos de búsqueda en la técnica particular y no se propone que sea limitante de la presente invención.
MX2020006754A 2017-12-27 2018-12-26 Moduladores de molécula pequeña de pantotenato-cinasas. MX2020006754A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762610835P 2017-12-27 2017-12-27
PCT/US2018/067539 WO2019133635A1 (en) 2017-12-27 2018-12-26 Small molecule modulators of pantothenate kinases

Publications (1)

Publication Number Publication Date
MX2020006754A true MX2020006754A (es) 2021-01-29

Family

ID=67068124

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020006754A MX2020006754A (es) 2017-12-27 2018-12-26 Moduladores de molécula pequeña de pantotenato-cinasas.
MX2024004440A MX2024004440A (es) 2017-12-27 2020-07-13 Moduladores de molécula pequeña de pantotenato-cinasas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024004440A MX2024004440A (es) 2017-12-27 2020-07-13 Moduladores de molécula pequeña de pantotenato-cinasas.

Country Status (12)

Country Link
US (2) US11891378B2 (es)
EP (1) EP3731844A4 (es)
JP (1) JP7352565B2 (es)
KR (1) KR102728619B1 (es)
CN (1) CN111818922B (es)
AU (1) AU2018395222B2 (es)
BR (1) BR112020012875A2 (es)
CA (1) CA3086671A1 (es)
IL (1) IL275658B2 (es)
MX (2) MX2020006754A (es)
SG (1) SG11202006047RA (es)
WO (1) WO2019133635A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020006754A (es) 2017-12-27 2021-01-29 St Jude Childrens Res Hospital Inc Moduladores de molécula pequeña de pantotenato-cinasas.
CA3086711A1 (en) 2017-12-27 2019-07-04 St. Jude Children's Research Hospital, Inc. Use of arylpiperazine-1-carboxamide derivatives in the treatment of coenzyme a-mediated disorders
WO2020198526A2 (en) * 2019-03-27 2020-10-01 St. Jude Children's Research Hospital Small molecule modulators of pank
JP2022081710A (ja) * 2019-03-29 2022-06-01 ユーティアイ リミテッド パートナーシップ 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用
AU2020250468A1 (en) * 2019-03-29 2021-11-04 Kinki University Use of T-type calcium channel blocker for treating pruritus
WO2023230560A1 (en) * 2022-05-26 2023-11-30 Coa Therapeutics, Inc. Treatment of organic acidemias or pantothenate kinase associated neurodegeneration with modulators of pantothenate kinases

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894063B2 (en) 2000-09-14 2005-05-17 Schering Corporation Substituted urea neuropeptide Y Y5 Receptor antagonists
US20050256130A1 (en) 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
CA2488202C (en) 2002-06-12 2011-03-08 Chemocentryx, Inc. 1-aryl-4-substituted piperazine derivatives for use as ccr1 antagonists for the treatment of inflammation and immune disorders
US7262194B2 (en) 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
TWI287010B (en) 2003-06-12 2007-09-21 Euro Celtique Sa Therapeutic agents useful for treating pain
JP4831577B2 (ja) 2003-07-30 2011-12-07 ゼノン・ファーマシューティカルズ・インコーポレイテッド ピリダジン誘導体および治療剤としての用途
US7759348B2 (en) 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
EP1758884A2 (en) 2004-05-20 2007-03-07 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
US7754724B2 (en) 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
CA2668811A1 (en) 2006-11-07 2008-06-05 Lexicon Pharmaceuticals, Inc. Methods of treating cognitive impairment and dementia
CN101294194A (zh) * 2007-04-28 2008-10-29 江苏先声药物研究有限公司 泛酸激酶药物筛选模型及其应用
AU2008269128B2 (en) 2007-06-25 2012-08-02 Amgen Inc. Phthalazine compounds, compositions and methods of use
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CN102803470A (zh) 2009-04-02 2012-11-28 佛罗里达大学研究基金会公司 针对生产琥珀酸路径的工程方法
BR112012004594A2 (pt) 2009-09-01 2016-06-21 Novozymes Inc célula hospedeira fúngica filamentosa, e, método para produzir um ácido dicarboxílico
US9187772B2 (en) 2010-09-01 2015-11-17 University Of Florida Research Foundation, Inc. L-malate production by metabolically engineered escherichia coli
UA114172C2 (uk) 2010-09-27 2017-05-10 Екселіксіс, Інк. Подвійні інгібітори мен і фрес для лікування кастраційно-резистентного раку простати та остеобластичних метастазів у кістці
CN103619825B (zh) 2011-07-01 2015-10-14 瑞敏德股份有限公司 可用于治疗神经退化性疾病的1,2,4-噻二唑-5-基哌嗪衍生物
TW201350478A (zh) 2012-05-11 2013-12-16 Abbvie Inc Ｎａｍｐｔ抑制劑
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
EP3060570B1 (en) * 2013-10-25 2018-09-19 Retrophin, Inc. Pantothenate derivatives for the treatment of neurological disorders
EP3283472B1 (en) 2015-04-17 2021-04-14 Indiana University Research & Technology Corporation Hepatitis b viral assembly effectors
WO2017223474A1 (en) * 2016-06-23 2017-12-28 St. Jude Children's Research Hospital Small molecule modulators of pantothenate kinases
CA3086711A1 (en) 2017-12-27 2019-07-04 St. Jude Children's Research Hospital, Inc. Use of arylpiperazine-1-carboxamide derivatives in the treatment of coenzyme a-mediated disorders
MX2020006754A (es) 2017-12-27 2021-01-29 St Jude Childrens Res Hospital Inc Moduladores de molécula pequeña de pantotenato-cinasas.
WO2019133634A1 (en) 2017-12-27 2019-07-04 St. Jude Children's Research Hospital Small molecule modulators of pantothenate kinases
WO2022133034A1 (en) 2020-12-16 2022-06-23 St. Jude Children's Research Hospital, Inc. Methods of treating disorders associated with castor

Also Published As

Publication number Publication date
US11891378B2 (en) 2024-02-06
RU2020124599A (ru) 2022-01-27
BR112020012875A2 (pt) 2021-01-05
IL275658B2 (en) 2024-04-01
AU2018395222A1 (en) 2020-08-13
KR20200130242A (ko) 2020-11-18
US20240287039A1 (en) 2024-08-29
EP3731844A4 (en) 2021-08-18
IL275658B1 (en) 2023-12-01
JP7352565B2 (ja) 2023-09-28
WO2019133635A1 (en) 2019-07-04
CN111818922A (zh) 2020-10-23
CA3086671A1 (en) 2019-07-04
CN111818922B (zh) 2023-06-13
SG11202006047RA (en) 2020-07-29
US20210061788A1 (en) 2021-03-04
JP2021508739A (ja) 2021-03-11
KR102728619B1 (ko) 2024-11-08
AU2018395222B2 (en) 2023-06-08
EP3731844A1 (en) 2020-11-04
IL275658A (en) 2020-08-31
MX2024004440A (es) 2024-05-08

Similar Documents

Publication Publication Date Title
MX2018015170A (es) Moduladores de moleculas peque?as de pantotenato cinasas.
MX2024004440A (es) Moduladores de molécula pequeña de pantotenato-cinasas.
CL2016001595A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6.
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MX2016013826A (es) Formulaciones de peroxido y metodos y aplicaciones para utilizarlas.
JO3794B1 (ar) المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
PH12014502803A1 (en) Camsylate salt
PH12019500467A1 (en) Benzo-fused heterocyclic derivatives useful agonists of gpr120
MX2017000524A (es) Compuestos novedosos de pirimidina sustituida.
PH12020550703A1 (en) Sulfonamide compounds and use thereof
MX2017008083A (es) Compuestos 2,3,4,5-tetrahidropiridin-6-amina y 3,4-dihidro-2h-pirrol-5-amina inhibidores de beta-secretasa.
MY176521A (en) Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising the same and use thereof
IN2014DN09584A (es)
BR112016018418A2 (pt) Composto, uso do mesmo, e composição farmacêutica
WO2020198526A3 (en) Small molecule modulators of pank
MX2016008715A (es) (r)-3-((3s,4s)-3-fluoro-4-(4-hidroxifenil)piperidin-1-il)-1-(4-me tilbencil) pirrolidin-2-ona y sus profarmacos para el tratamiento de trastornos psiquiatricos.
MX2021004322A (es) Uso de lecitinas como biocida contra artropodos.
CL2008001500A1 (es) Compuestos derivados de hidroxietil amina sustituidas, moduladores de betasecretasa; proceso de preparacion de dichos c ompuestos; composicion farmaceutica que los comprende; y su uso para tratar un trastorno neurologico, tal como alzheimer, sindrome de down, demencia degenerativa, entre otros.
MX2016010268A (es) Pirimidinimidazolaminas como modulares de actividad de cinasa.
MX2016011629A (es) Derivados de pirrol biciclicos utiles como agonistas de gpr120.
BR112017025901A2 (pt) composto, composição farmacêutica e uso de um composto
MX2016015959A (es) Derivados de carbamato los cuales son tanto inhibidores de la enzima fosfodiesterasa 4 (pde4) como antagonistas del receptor muscarinico m3.
MX2019006144A (es) Una nueva forma cristalina de oxamilo, un proceso para su preparacion y uso de esta.
MX2015016506A (es) Una mezcla enriquecida con la estereoquimica r,r de 3',4'-di-o-acetil-cis-quelactona para el tratamiento de la diabetes mellitus.
AU2018258348A1 (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders